SCHEDULE 13G/A: BlackRock Boosts BioMarin Stake to 9.1%
Beneficial Ownership Report
BlackRock, Inc. has reported a 9.1% beneficial ownership stake in BioMarin Pharmaceutical Inc., holding 17,560,751 common shares as of December 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 17,560,751 shares of BioMarin Pharmaceutical Inc. common stock.
- This represents 9.1% of BioMarin Pharmaceutical Inc.'s total outstanding common stock.
- BlackRock holds sole voting power over 16,727,815 shares and sole dispositive power over 17,560,751 shares.
- The filing is an Amendment No. 13 to a Schedule 13G, indicating a routine update by a passive institutional investor.
- BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioMarin Pharmaceutical Inc.
Sentiment
Score: 5
Explanation: The filing is a routine Schedule 13G amendment disclosing an institutional investor's beneficial ownership, which is a neutral event in itself. It does not contain positive or negative information regarding the issuer's performance or future prospects.
Positives
- NA This filing is a beneficial ownership report and does not contain information on the issuer's operational or financial performance.
Negatives
- NA This filing is a beneficial ownership report and does not contain information on the issuer's operational or financial performance.
Risks
- NA This filing is a beneficial ownership report and does not contain information on the issuer's operational or financial performance or specific risks related to the investment.
Future Outlook
NA This filing is a beneficial ownership report and does not provide forward-looking statements or guidance from the issuer or the reporting entity regarding the issuer's future performance.
Industry Context
Schedule 13G filings are routine disclosures by institutional investors, such as BlackRock, when their beneficial ownership in a public company exceeds 5% and they hold the shares passively. This filing indicates BlackRock's continued significant, but passive, investment in BioMarin Pharmaceutical Inc., a common practice for large asset managers diversifying their portfolios across various industries, including biotechnology.
Stakeholder Impact
- Shareholders: Confirms a significant institutional investor's continued passive stake, potentially signaling confidence in BioMarin's long-term prospects without indicating any intent to influence control.
- Management: Provides transparency regarding a major shareholder's position, but BlackRock's passive stance suggests no immediate pressure or influence on management decisions.
Key Dates
| Date | Description |
|---|---|
| 2025-01-21 | Execution date of the new Power of Attorney by BlackRock, Inc., revoking a previous one. |
| 2025-12-31 | Date of event requiring the filing of this statement, representing the end of the reporting period for beneficial ownership of BioMarin Pharmaceutical Inc. shares. |
| 2026-01-21 | Date of signature for the Schedule 13G/A filing by BlackRock, Inc. |
Keywords
BlackRock, BioMarin Pharmaceutical Inc., Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Equity Stake, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.